Skip to main content

Table 4 Outcomes of KRAS/RAS testing in Round 3 of the medical records review study

From: Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

Outcome No. of patients (%)
All patients RAS(N = 109) KRAS(N = 22) Total(N = 131)
Tested for mutation status prior to first dose of panitumumab 109 (100.0) 22 (100.0) 131 (100.0)
Wild-type mutation status test result confirmed prior to first dose of panitumumab 109 (100.0) 22 (100.0) 131 (100.0)
Subset of patients treated with concurrent oxaliplatin-containing therapy RAS (N = 64) KRAS (N = 7) Total (N = 71)
Tested for mutation status prior to first dose of panitumumab 64 (100.0) 7 (100.0) 71 (100.0)
Wild-type mutation status test result confirmed prior to first dose of panitumumab 64 (100.0) 7 (100.0) 71 (100.0)